journal
MENU ▼
Read by QxMD icon Read
search

Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine

journal
https://www.readbyqxmd.com/read/30630944/performance-characteristics-of-the-digital-biograph-vision-pet-ct-system
#1
Joyce J van Sluis, Johan de Jong, Jenny Schaar, Walter Noordzij, Paul van Snick, Rudi Dierckx, Ronald Borra, Antoon Willemsen, Ronald Boellaard
This study evaluates the performance of the Siemens Biograph Vision digital PET/CT system (Siemens Healthineers, Knoxville, USA) according to the NEMA NU 2-2012 standard (published by the National Electrical Manufacturers Association (NEMA)) to allow for a reliable, reproducible, and inter-system comparable performance measurement. Methods: The new digital PET/CT features silicon photomultiplier (SiPM)-based detectors with 3.2 mm lutetium oxyorthosilicate (LSO) crystals and full coverage of the scintillator area...
January 10, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30630943/reply-radiation-dose-does-matter-mechanistic-insights-into-dna-damage-and-repair-support-the-linear-no-threshold-model-of-low-dose-radiation-health-risks
#2
James R Duncan, Michael R Lieber, Noritaka Adachi, Richard L Wahl
No abstract text is available yet for this article.
January 10, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30630942/development-and-in-vivo-evaluation-of-a-novel-kappa-opioid-receptor-agonist-as-pet-radiotracer-with-superior-imaging-characteristics
#3
Songye Li, Ming-Qiang Zheng, Mika Naganawa, Sujin Kim, Hong Gao, Michael Kapinos, David Labaree, Yiyun Huang
Studies have shown kappa opioid receptor (KOR) abnormalities in addictive disorders and other central nervous system diseases and Alzheimer's disease. We have developed the first set of agonist 11 C-GR103545 and antagonist 11 C-LY2795050 radiotracers for positron emission tomography imaging of KOR in human. Nonetheless, 11 C-GR103545 displays protracted uptake kinetics and is not an optimal radiotracer. Here we report the development and evaluation of 11 C-EKAP and its comparison with 11 C-GR103545. Methods: EKAP was synthesized and assayed for in vitro binding affinities, then radiolabeled with 11 C-CH3 OTf...
January 10, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30630941/healthy-tissue-uptake-of-68-ga-prostate-specific-membrane-antigen-psma-18-f-dcfpyl-18-f-fluoromethylcholine-fch-and-18-f-dihydrotestosterone-fdht
#4
Bernard H E Jansen, Gerbrand M Kramer, Matthijs C F Cysouw, Maqsood M Yaqub, Bart de Keizer, Jules Lavalaye, Jan Booij, Hebert Alberto Vargas, Michael J Morris, André N Vis, Reindert van Moorselaar, Otto S Hoekstra, Ronald Boellaard, Daniela E Oprea-Lager
Positron Emission Tomography (PET) is increasingly used for prostate cancer (PCa) diagnostics. Important PCa radiotracers include 68 Ga-Prostate-Specific Membrane Antigen HBED-CC (68 Ga-PSMA), 18 F-DCFPyL, 18 F-fluoromethylcholine (18 F-FCH) and 18 F-dihydrotestosterone (18 F-FDHT). Knowledge on the variability of tracer uptake in healthy tissues is important for accurate PET interpretation, since malignancy is suspected only if the uptake of a lesion contrasts with its background. Therefore, the aim of this study was to quantify uptake variability of PCa tracers in healthy tissues and identify stable reference regions for PET interpretation...
January 10, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30630940/impact-of-p-glycoprotein-function-on-the-brain-kinetics-of-the-weak-substrate-11-c-metoclopramide-assessed-with-pet-imaging-in-humans
#5
Nicolas Tournier, Martin Bauer, Verena Pichler, Lukas Nics, Eva-Maria Klebermass, Karsten Bamminger, Peter Matzneller, Maria Weber, Rudolf Karch, Fabien Caille, Sylvain Auvity, Solene Marie, Walter Jaeger, Wolfgang Wadsak, Marcus Hacker, Markus Zeitlinger, Oliver Langer
PET with avid substrates of P-glycoprotein (ABCB1) provided evidence of the role of this efflux transporter in effectively restricting the brain penetration of its substrates across the human blood-brain barrier (BBB). This may not reflect the situation for weak ABCB1 substrates including several antidepressants, antiepileptic drugs and neuroleptics, which exert CNS effects despite being transported by ABCB1. We performed PET with the weak ABCB1 substrate 11 C-metoclopramide in humans to elucidate the impact of ABCB1 function on its brain kinetics...
January 10, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30630939/pet-imaging-of-parp-expression-using-18-f-olaparib
#6
Delphine L Chen
No abstract text is available yet for this article.
January 10, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30630938/roadmap-for-the-development-and-gmp-translation-of-optical-tracers-cetuximab-800cw-and-trastuzumab-800cw
#7
Matthijs D Linssen, Eva J Ter Weele, Derk P Allersma, Marjolijn N Lub-de Hooge, Gooitzen van Dam, Annelies Jorritsma-Smit, Wouter Nagengast
Optical molecular imaging using fluorescently labeled monoclonal antibodies is of significant added value to guide surgical or endoscopic procedures. However, development of tracers for clinical trials is complex, and therefore implementation in the clinic is slow. We present a roadmap for development and translation of monoclonal antibody tracers into a current Good Manufacturing Process (cGMP) compliant drug product. Methods: The production process of cetuximab-800CW and trastuzumab-800CW was optimized with regard to dye to protein label ratio and formulation buffer...
January 10, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30573643/reply-to-different-radionuclides-in-dota-eb-tate-effect-different-uptake-in-somatostatin-receptor-positive-hek293-cells
#8
Orit Jacobson Weiss, Xiaoyuan Chen
No abstract text is available yet for this article.
December 20, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30573642/new-developments-in-peptide-receptor-radionuclide-therapy
#9
Guillaume P Nicolas, Alfred Morgenstern, Margret Schottelius, Melpomeni Fani
Peptide Receptor Radionuclide Therapy (PRRT) is an established treatment for non-operable or metastatic neuroendocrine neoplasms that express highly and frequently somatostatin receptors. More generally, PRRT is an attractive therapy option for delivering cytotoxic radiation to tumor cells through specific binding of a radiolabeled peptide to a molecular target. The development of imaging companions gave rise to the concept of radiotheranostics, important for in vivo tumor detection, characterization, staging but also, and more importantly, for individual patient selection and treatment...
December 20, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30573641/the-challenges-and-opportunities-in-functional-imaging-her2-positive-breast-cancers
#10
Joanne E Mortimer
No abstract text is available yet for this article.
December 20, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30573640/entering-the-era-of-molecular-targeted-precision-surgery-in-recurrent-prostate-cancer
#11
Tobias Maurer, Fijs W B van Leeuwen, Margret Schottelius, Hans-Jürgen Wester, Matthias Eiber
No abstract text is available yet for this article.
December 20, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30573639/the-availability-of-the-%C3%AE-7-nicotinic-acetylcholine-receptor-in-recent-onset-psychosis-a-study-using-18-f-asem-pet
#12
Jennifer Coughlin, Yong Du, Jeffrey L Crawford, Leah H Rubin, Babak Behnam Azad, Wojciech G Lesniak, Andrew G Horti, David J Schretlen, Akira Sawa, Martin G Pomper
Limited postmortem evidence suggests a diminished availability of the α7 nicotinic acetylcholine receptor (α7-nAChR) in hippocampus in psychosis. Methods: In this cross-sectional PET study, we used 18 F-ASEM, a radiotracer targeting the α7-nAChR, with positron emission tomography to compare the binding of 18 F-ASEM in hippocampus between individuals with recent-onset psychosis and healthy controls. Results: Individuals with recent-onset psychosis [non-affective psychosis (NP) or affective psychosis], and particularly those with NP, showed lower hippocampal binding of 18 F-ASEM than healthy controls...
December 20, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30552204/-n-2-dimethylamino-ethyl-4-18-f-fluorobenzamide-a-novel-molecular-probe-for-high-contrast-pet-imaging-of-malignant-melanoma
#13
Ayoung Pyo, Hyeon-Sik Kim, Gyeongmin Kim, Hyung-Seok Kim, Misun Yun, Dong-Yeon Kim, Jung-Joon Min
Malignant melanoma is a very aggressive and serious form of skin cancer, with prognosis and treatment outcome depending heavily on the clinical stage of the disease at the time of diagnosis. Here, we synthesized a novel 18 F-labeled benzamide derivative to target melanoma, and then evaluated its biological characteristics in small animal models. Methods : N -(2-(dimethylamino)ethyl)-4-18 F-fluorobenzamide (18 F-DMFB) was synthesized by reaction of N -succinimidyl 4-18 F-fluorobenzoate with N , N -dimethylethylenediamine...
December 14, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30552203/impact-of-68-ga-psma-pet-ct-on-the-radiotherapeutic-approach-for-prostate-cancer-in-comparison-to-ct-a-retrospective-analysis
#14
Nina-Sophie Schmidt-Hegemann, Eze Chukwuka, Li Minglun, Paul Rogowski, Christian Schaefer, Christian Stief, Alexander Buchner, Constantinos Zamboglou, Wolfgang P Fendler, Ute Ganswindt, Clemens Cyran, Peter Bartenstein, Claus Belka, Harun Ilhan
68 Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography (68 Ga-PSMA PET/CT) offers unprecedented accuracy for staging of primary, persistent or recurrent prostate cancer. Thus, we hypothesized that PSMA PET/CT prior to radiotherapy significantly impacts the radiotherapeutic approach in comparison to the current standard of CT based approach. Methods: Between February 2014 and December 2017, a total of 172 patients received PSMA PET/CT before radiotherapy and were included in this retrospective analysis...
December 14, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30552202/-18-f-fdg-pet-ct-guided-treatment-duration-in-patients-with-high-risk-staphylococcus-aureus-bacteremia-a-proof-of-principle
#15
Marvin A H Berrevoets, Ilse J E Kouijzer, Kitty Slieker, Erik Aarntzen, Bart Jan Kullberg, Jaap Ten Oever, Chantal P Bleeker-Rovers
Objectives: Current guidelines recommend intravenous antibiotic therapy for at least 4 weeks in patients with high-risk Staphylococcus aureus bacteremia (SAB), because of the risk for metastatic infection. We evaluated the safety of shorter duration of treatment in patients with high-risk SAB without signs of metastatic infection at presentation, using standard 18 F-FDG PET/CT and echocardiography. Methods: Retrospective analyses were performed of patients with SAB admitted between 2013 and 2017 in two medical centers...
December 14, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30552201/combination-of-68-ga-psma-pet-ct-and-multiparameter-mri-improves-the-detection-of-clinically-significant-prostate-cancer-a-lesion-by-lesion-analysis
#16
Mengxia Chen, Qing Zhang, Chengwei Zhang, Xiaozhi Zhao, Giancarlo Marra, Jie Gao, Xiaoyu Lv, Bing Zhang, Yao Fu, Feng Wang, Xuefeng Qiu, Hongqian Guo
Purpose: To explore whether 68 Ga-PSMA PET/CT (PET/CT) or the combination of mpMRI and 68 Ga-PSMA PET/CT (com-MRI/PET) can improve the detection of csPCa. Methods: We retrospectively enrolled 54 patients who underwent both mpMRI and PET/CT before radical prostatectomy. Regions of interest (ROI) on imaging from mpMRI, PET/CT and pathology were marked. A lesion was defined when ROI was marked in the same location on continuous imaging at any of the imaging setting. All lesions were recorded by Prostate Imaging Reporting and Data System (PI-RADS), miPSMA expression score (MI-ES) and pathology results and analyzed...
December 14, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30552200/rapid-modulation-of-psma-expression-by-androgen-deprivation-serial-68-ga-psma-11-pet-in-men-with-hormone-sensitive-and-castrate-resistant-prostate-cancer-commencing-androgen-blockade
#17
Louise M Emmett, Charlotte Yin, Megan Crumbaker, George Hruby, Andrew Kneebone, Richard Epstein, Quco Nguyen, Adam Hickey, Noah Ihsheish, Gordon O'Neill, Lisa Hovarth, Venu Chalasani, Phillip Stricker, Anthony Joshua
Prostate specific membrane antigen (PSMA) may be targeted for both diagnostic and therapeutic purposes in the management of prostate cancer (PCa). In pre-clinical models, androgen blockade (AB) increases expression of PSMA in both hormone sensitive and castrate resistant xenotypes. The aim of this study was to evaluate the effect of AB treatment on Ga68PSMA-11 PET imaging in hormone naive (Luteinising hormone-releasing hormone (LHRH) ± bicalutamide), and in castrate resistant men (enzalutamide or abiraterone) with metastatic PCa...
December 14, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30552199/albumin-binding-psma-ligands-implications-for-expanding-the-therapeutic-window
#18
James M Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala, Anastasia Nikolopoulou, Clarence Williams, Stephen G DiMagno, John Babich
Despite significant gains in the treatment of metastatic castration-resistant prostate cancer by radioligands targeting PSMA, 30% of patients never respond to therapy. One possible explanation is insufficient dose delivery to the tumor, which is related to suboptimal pharmacokinetics. We have recently described RPS-063, a trifunctional ligand targeting PSMA with high uptake in LNCaP xenograft tumors, but also in kidneys. We aimed to use structural modifications to increase the tumor-to-kidney ratio through increased albumin binding and tumor uptake and reduction of kidney activity...
December 14, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30530832/quantitative-analysis-of-18-f-pf-06684511-a-novel-pet-radioligand-for-selective-%C3%AE-secretase-1-imaging-in-non-human-primate-brain
#19
Akihiro Takano, Laigao Chen, Sangram Nag, Michael A Brodney, Ryosuke Arakawa, Cheng Chang, Nahid Amini, Shawn D Doran, Jason K Dutra, Timothy J McCarthy, Charles E Nolan, Brian T O'Neill, Anabella Villalobos, Lei Zhang, Christer Halldin
Beta-secretase 1 (BACE1) is a key enzyme in the generation of beta-amyloid, which is accumulated in the brain of Alzheimer's disease (AD) patients. PF-06684511 was identified as a candidate PET ligand for imaging BACE1 in the brain, and showed high specific binding in an initial assessment in a non-human primate (NHP) PET study utilizing 18 F-PF-06684511. In this effort, we aimed to quantitatively evaluate the regional brain distribution of 18 F-PF-06684511 in NHPs under baseline and blocking conditions as well as assess the target occupancy of BACE1 inhibitors...
December 7, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/30530831/meta-analysis-of-68-ga-psma-11-pet-accuracy-for-the-detection-of-prostate-cancer-validated-by-histopathology
#20
Thomas A Hope, Jeremy Z Goodman, Isabel E Allen, Jeremie Calais, Wolfgang P Fendler, Peter R Carroll
Background: 68 Ga-PSMA-11 PET is used to stage patients with prostate cancer. We performed an updated meta-analysis, which separates imaging at the time of diagnosis and that at the time of biochemical recurrence, and focuses on pathology correlation in both populations. Methods: We searched MEDLINE and EMBASE databases using the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. A random effect model and a hierarchical summary receiver operating characteristic model was used to summarize the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for pelvic lymph nodes in initial staging compared to pathology at prostatectomy, and the PPV for lesions with pathologic correlation in those with biochemical recurrence...
December 7, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
journal
journal
20164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"